While studying Parkinson's disease, an international research group made a discovery which can improve industrial protein synthesis for therapeutic use. They managed to understand a novel function of ...

Dublin, Nov. 19, 2024 (GLOBE NEWSWIRE) -- The "Antisense and RNAi Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for ...

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target ...

Arnatar Therapeutics has unveiled with $52 million in series A financing to bankroll new RNA-based therapies, including a candidate that takes aim at a rare genetic disease called Alagille syndrome ...

Emerging modalities such as self-amplifying and circular RNA, expanding oncology and rare-disease applications, and scalable manufacturing are creating high-growth investment avenues, supported by ...

Researchers from Osaka University have developed a novel approach to target nicotinamide N-methyltransferase (NNMT), an enzyme implicated in cancer progression, using antisense oligonucleotides (ASOs) ...

Patients receiving a kidney transplant and who are positive for BK virus (BKV) are at risk of losing their transplant due to BKV reactivation. At this time, there are no antiviral options available ...

The global antisense oligonucleotides market is poised for remarkable growth over the next decade, projected to rise from USD 2,913.5 million in 2023 to USD 5,519.6 million by 2033 moving forward with ...